Flunisolide hemihydrate is a corticosteroid, which is an orally activeglucocorticoid receptoractivator withanti-inflammatoryactivity. Flunisolide hemihydrate can induce eosinophilapoptosis, and is used for the research of asthma or rhinitis, and inflammation^[1][2].

Flunisolide hemihydrate (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation^[1].
Flunisolide hemihydrate (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated from mild to moderate asthmatics), and induces sputum eosinophil apoptosis^[2].
Flunisolide hemihydrate (0.1-10 μM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells^[3].
Flunisolide hemihydrate (115 μM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent^[4].

Flunisolide hemihydrate (Intranasal administration, 0.3-10 μg/mouse, daily, from days 21–27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice^[1].
Flunisolide hemihydrate (Intranasal administration, 0.3-10 μg/mouse, daily, from days 21–27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue^[1].

443.51

C₂₄H₃₃FO₇

77326-96-6

氟尼缩松半水合物

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.